get a key
steadybase-$ company BLCO
account_id none on file
legal_name Bausch & Lomb Corp
ticker BLCO
cik 1860742
domain bausch.com
entry_point_account_id none on file
name Bausch + Lomb Corporation
exchange NYSE
sector Health Care
calls 1 filings 10 executives 3 family 0
why_nownone on file
calls
Can you maybe help us think about just the direction of travel in the consumer franchise how we should expect some of these different, whether it's a limified driving growth or how we should think about some of the different factors in 26 in that franchise?

Feb 18, 2026 / receipt, needs a key / David Roman, Analyst | earnings call 2026-02-18 | transcript c527df15-5010-4f2d-bfb5-ec4a4376d4af | chars 49052-49309 | segment 50

filings
Under the former Biden administration, many of these changes focused on health care cost containment, which resulted in pricing pressures relating to the sales and reimbursements of health care products and could result in legislative and regulatory changes that may negatively impact our businesses.

filing / Jul 29, 2026 / receipt

The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses.

filing / Jul 29, 2026 / receipt

Restructuring, integration and separation costs for the six months ended June 30, 2026 and 2025 were $ 12 million and $ 32 million, respectively, and primarily consist of employee severance costs.

filing / Jul 29, 2026 / receipt

These severance costs were provided under an ongoing benefit arrangement and were therefore recorded once they were both probable and reasonably estimable in accordance with the provisions of ASC 712-10, “Nonretirement Postemployment Benefits”.

filing / Jul 29, 2026 / receipt

Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of June 30, 2026.

filing / Jul 29, 2026 / receipt

Under the former Biden administration, many of these changes focused on health care cost containment, which resulted in pricing pressures relating to the sales and reimbursements of health care products and could result in legislative and regulatory changes that may negatively impact our businesses.

filing / Apr 29, 2026 / receipt

The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses.

filing / Apr 29, 2026 / receipt

Restructuring, integration and separation costs for the three months ended March 31, 2026 and 2025 were $ 8 million and $ 1 million, respectively, and primarily consist of employee severance costs.

filing / Apr 29, 2026 / receipt

These severance costs were provided under an ongoing benefit arrangement and were therefore recorded once they were both probable and reasonably estimable in accordance with the provisions of ASC 712-10, “Nonretirement Postemployment Benefits”.

filing / Apr 29, 2026 / receipt

Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of March 31, 2026.

filing / Apr 29, 2026 / receipt

executives
Andrew Stewart President of Global Pharmaceuticals and - receipt
Brent Saunders CEO - receipt
Sam Aldasuki Chief Financial Officer - receipt
familynone on file
upcoming
2026-11-04 earnings call scheduled webcast / ir
changes
2023-02-15 Chief Executive Officer, departed sec_8k
mcp_package_hint
steadybase-$